Drug major Lupin on Wednesday announced the launch of its Favipiravir drug under the brand name ‘Covihalt’ for the treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per tablet in India.
Favipiravir has received authorization from the Drug Controller General of India (DCGI) for emergency use.
Favipiravir was originally developed by Japan’s Fujifilm Holdings Corp under the brand name Avigan for treating influenza.
Its Covihalt dosage strength has been developed keeping in mind convenience of administration, it stated, adding that the drug is available as 200 mg tablets in the form of a strip of 10 tablets, and priced at Rs 49 per tablet.
Lupin President – India Region Formulations (IRF) Rajeev Sibal said the company believes that it can leverage its expertise in managing widespread community diseases like tuberculosis to proactively reach patients across India and ensure access to Covihalt through its strong distribution network and field force.
On August 4, Sun Pharmaceutical Industries had launched Favipiravir under the brand name ”FluGuard” for the treatment of mild to moderate cases of COVID-19, at Rs 35 per tablet in India
Other Indian drugmakers developing or selling favipiravir include Glenmark Pharmaceuticals, Hetero and Cipla.
Another Indian pharma company Zydus Cadila today said its COVID-19 vaccine candidate, ZyCoV-D, was found to be safe and well tolerated in the Phase I clinical trial. The company will now commence Phase II clinical trials from the 6th of August, 2020.